Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy

Author(s): Marco L. Rossi , Dennis Zavalloni , Guido Belli , Patrizia Presbitero .

Journal Name: Letters in Drug Design & Discovery

Volume 2 , Issue 7 , 2005

Become EABM
Become Reviewer


Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.

Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [503 - 506]
Pages: 4
DOI: 10.2174/157018005774479168
Price: $58